vs
Side-by-side financial comparison of AMPCO PITTSBURGH CORP (AP) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $104.4M, roughly 1.7× AMPCO PITTSBURGH CORP). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -55.2%, a 56.9% gap on every dollar of revenue. On growth, AMPCO PITTSBURGH CORP posted the faster year-over-year revenue change (11.5% vs 5.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -2.6%).
Ampco-Pittsburgh Corporation is a specialty steel manufacturer headquartered in Downtown Pittsburgh, Pennsylvania. It is one of several companies to bear the Ampco name, and it should not be confused with the Milwaukee-based copper base alloy producer, Ampco Metal Inc.; the Miami-based cabinetry company; the Swiss aluminum corporation; or the Dallas-based tool company. Ampco was formed in 1929 and is a conglomerate made up of several previously established small steel makers. Five small compa...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
AP vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $104.4M | $177.4M |
| Net Profit | $-57.7M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | -54.0% | 3.9% |
| Net Margin | -55.2% | 1.6% |
| Revenue YoY | 11.5% | 5.0% |
| Net Profit YoY | -1958.9% | — |
| EPS (diluted) | $-2.87 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $104.4M | $196.9M | ||
| Q3 25 | $103.7M | $179.5M | ||
| Q2 25 | $108.9M | $181.1M | ||
| Q1 25 | $99.2M | $168.9M | ||
| Q4 24 | $93.6M | $187.3M | ||
| Q3 24 | $92.1M | $168.6M | ||
| Q2 24 | $107.1M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-57.7M | — | ||
| Q3 25 | $-2.2M | $5.4M | ||
| Q2 25 | $-7.3M | $-4.8M | ||
| Q1 25 | $1.1M | $4.8M | ||
| Q4 24 | $3.1M | — | ||
| Q3 24 | $-2.0M | $-143.5M | ||
| Q2 24 | $2.0M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -54.0% | 1.2% | ||
| Q3 25 | 1.1% | 3.5% | ||
| Q2 25 | -2.8% | 4.7% | ||
| Q1 25 | 3.9% | 1.2% | ||
| Q4 24 | 5.5% | 13.2% | ||
| Q3 24 | 2.0% | -82.8% | ||
| Q2 24 | 4.7% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -55.2% | — | ||
| Q3 25 | -2.1% | 3.0% | ||
| Q2 25 | -6.7% | -2.7% | ||
| Q1 25 | 1.2% | 2.8% | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | -2.1% | -85.1% | ||
| Q2 24 | 1.9% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-2.87 | $0.05 | ||
| Q3 25 | $-0.11 | $0.12 | ||
| Q2 25 | $-0.36 | $-0.11 | ||
| Q1 25 | $0.06 | $0.10 | ||
| Q4 24 | $0.16 | $0.38 | ||
| Q3 24 | $-0.10 | $-3.11 | ||
| Q2 24 | $0.10 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.7M | $144.3M |
| Total DebtLower is stronger | $117.9M | — |
| Stockholders' EquityBook value | $32.6M | $653.9M |
| Total Assets | $495.4M | $1.2B |
| Debt / EquityLower = less leverage | 3.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $10.7M | $238.4M | ||
| Q3 25 | $15.0M | $246.3M | ||
| Q2 25 | $9.9M | $445.9M | ||
| Q1 25 | $7.1M | $493.6M | ||
| Q4 24 | $15.4M | $484.6M | ||
| Q3 24 | $11.8M | $453.8M | ||
| Q2 24 | $7.9M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $117.9M | $372.2M | ||
| Q3 25 | $119.0M | $376.7M | ||
| Q2 25 | $115.9M | $580.5M | ||
| Q1 25 | $115.0M | $583.4M | ||
| Q4 24 | $116.4M | $585.3M | ||
| Q3 24 | $116.0M | — | ||
| Q2 24 | $119.4M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $32.6M | $693.1M | ||
| Q3 25 | $60.1M | $727.2M | ||
| Q2 25 | $62.7M | $757.8M | ||
| Q1 25 | $64.6M | $798.5M | ||
| Q4 24 | $58.9M | $778.3M | ||
| Q3 24 | $61.3M | $749.6M | ||
| Q2 24 | $58.0M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $495.4M | $1.3B | ||
| Q3 25 | $524.4M | $1.3B | ||
| Q2 25 | $537.2M | $1.5B | ||
| Q1 25 | $536.2M | $1.6B | ||
| Q4 24 | $530.9M | $1.6B | ||
| Q3 24 | $547.4M | $1.5B | ||
| Q2 24 | $560.8M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 3.61× | 0.54× | ||
| Q3 25 | 1.98× | 0.52× | ||
| Q2 25 | 1.85× | 0.77× | ||
| Q1 25 | 1.78× | 0.73× | ||
| Q4 24 | 1.98× | 0.75× | ||
| Q3 24 | 1.89× | — | ||
| Q2 24 | 2.06× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.7M | — |
| Free Cash FlowOCF − Capex | $-64.0K | — |
| FCF MarginFCF / Revenue | -0.1% | — |
| Capex IntensityCapex / Revenue | 2.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-8.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $2.7M | $43.7M | ||
| Q3 25 | $6.3M | $60.8M | ||
| Q2 25 | $-2.3M | $12.0M | ||
| Q1 25 | $-5.3M | $35.5M | ||
| Q4 24 | $7.5M | $33.1M | ||
| Q3 24 | $11.4M | $53.9M | ||
| Q2 24 | $-5.3M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-64.0K | $43.5M | ||
| Q3 25 | $3.3M | $57.0M | ||
| Q2 25 | $-3.8M | $9.3M | ||
| Q1 25 | $-7.5M | $26.9M | ||
| Q4 24 | $3.7M | $31.0M | ||
| Q3 24 | $8.4M | $49.8M | ||
| Q2 24 | $-8.0M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -0.1% | 22.1% | ||
| Q3 25 | 3.2% | 31.7% | ||
| Q2 25 | -3.5% | 5.1% | ||
| Q1 25 | -7.5% | 15.9% | ||
| Q4 24 | 4.0% | 16.6% | ||
| Q3 24 | 9.1% | 29.6% | ||
| Q2 24 | -7.5% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 0.1% | ||
| Q3 25 | 2.9% | 2.2% | ||
| Q2 25 | 1.3% | 1.5% | ||
| Q1 25 | 2.2% | 5.1% | ||
| Q4 24 | 4.0% | 1.1% | ||
| Q3 24 | 3.2% | 2.4% | ||
| Q2 24 | 2.5% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | -4.62× | 7.37× | ||
| Q4 24 | 2.40× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2.64× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AP
| Forged And Cast Mill Rolls | $67.0M | 64% |
| Air Handling Systems | $14.3M | 14% |
| Heat Exchange Coils | $13.1M | 13% |
| Centrifugal Pumps | $10.3M | 10% |
| Forged Engineered Products | $4.0M | 4% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
